Keurig Dr Pepper Inc. tapped Rafael Oliveira , chief executive officer of recently acquired JDE Peet’s NV , to lead its new coffee company once the integration of the Dutch firm and split into two entities is complete. Oliveira has been with JDE Peet’s since November 2024. Keurig had previously named Sudhanshu Priyadarshi , at the time its chief financial officer, to lead the coffee company but ch...
Keurig Dr Pepper Inc. tapped Rafael Oliveira , chief executive officer of recently acquired JDE Peet’s NV , to lead its new coffee company once the integration of the Dutch firm and split into two entities is complete. Oliveira has been with JDE Peet’s since November 2024. Keurig had previously named Sudhanshu Priyadarshi , at the time its chief financial officer, to lead the coffee company but changed course in October amid investor skepticism over the amount of debt it plans to take on to acquire JDE Peet’s. Keurig said last August it planned to acquire JDE Peet’s and then divide the combined company into two separate entities: a beverage company led by current Keurig CEO Tim Cofer that would house its fast-growing Dr Pepper soda, among others, and a coffee company. It hopes to be ready for the split by the end of the year, according to a statement Wednesday. “Having launched a brand-led strategy at JDE Peet’s that is already delivering tangible results, Rafa is uniquely positioned to set the direction for Global Coffee Co.,” Cofer said. Oliveira previously spent a decade at Kraft Heinz Co. Keurig has twice raised additional capital to reduce its debt levels and win over investors. Priyadarshi was replaced by Anthony DiSilvestro as CFO.
Tesla is slated to report first-quarter delivery figures on Thursday. Shares of the electric-vehicle maker were up 1.4% at $376.76 in premarket trading Wednesday, while and futures were both up about 0.5%. Wall Street is expecting about 366,000 vehicles sold in the first quarter, up from 337,000 a year ago.
Tesla is slated to report first-quarter delivery figures on Thursday. Shares of the electric-vehicle maker were up 1.4% at $376.76 in premarket trading Wednesday, while and futures were both up about 0.5%. Wall Street is expecting about 366,000 vehicles sold in the first quarter, up from 337,000 a year ago.
aprott/iStock via Getty Images Novo Nordisk’s ( NVO ) GLP-1 drug Wegovy (semaglutide) will reach a larger base of patients in the UK with new recommendations from the National Institute for Health and Care Excellence. NICE has recommended the injectable drug to over 1M people to prevent stroke and heart attack, particularly those who have an elevated risk or circulation issues in the leg, and over...
aprott/iStock via Getty Images Novo Nordisk’s ( NVO ) GLP-1 drug Wegovy (semaglutide) will reach a larger base of patients in the UK with new recommendations from the National Institute for Health and Care Excellence. NICE has recommended the injectable drug to over 1M people to prevent stroke and heart attack, particularly those who have an elevated risk or circulation issues in the leg, and overweight patients. The medication, popular for weight loss, will be offered above current drugs being offered to the patient population, including statins. NICE noted that clinical trial data showed Wegovy was linked to a lower risk of heart attack, stroke or cardiovascular death, and the benefit was seen even before significant weight loss occured. The new recommendations cover adults who previously suffered a heart attack or stroke, or have peripheral arterial disease or a body mass index of at least 27. “Around 1.2 million people could use semaglutide to help protect them against having further heart attacks or strokes as the medicine is made available for this condition,” the statement added. “We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. Today's decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking,” NICE said in its statement on 1 April. More on Novo Nordisk A/S Novo Nordisk: Why I Still Find It An Interesting Opportunity Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market Novo Nordisk A/S (NOVO:CA) Shareholder/Analyst Call Transcript Novo’s China obesity drug posts positive mid-stage trial results Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Sergio Delle Vedove Nike ( NKE ) is on the radar of analysts and investors after reporting a year-over-year decline in profit and issuing guidance below expectations. The report is being seen as an indication of an uneven recovery for the athletic apparel giant. RBC Capital Markets analyst Piral Dadhania said the firm remains constructive on Nike's ( NKE ) mid-term recovery potential. However, the...
Sergio Delle Vedove Nike ( NKE ) is on the radar of analysts and investors after reporting a year-over-year decline in profit and issuing guidance below expectations. The report is being seen as an indication of an uneven recovery for the athletic apparel giant. RBC Capital Markets analyst Piral Dadhania said the firm remains constructive on Nike's ( NKE ) mid-term recovery potential. However, the shape of recovery is now seen as taking longer than initially anticipated, largely due to the Greater China, Converse, and sportswear drags. On the positive side, Dadhania said Nike ( NKE ) management appears willing to take hard decisions to address shortcomings and reset the business for longer-term sustainable growth, with the Win Now playbook considered as the right strategy. RBC Capital lowered its price target on Nike ( NKE ) to $70 while maintaining an Outperform rating. BTIG clipped its price target on Nike ( NKE ) to $75 as it pointed to a recovery taking longer than anticipated. Analyst Robert Drbul and his team are still confident about the long-term trajectory for the Buy-rated stock. "Margins are expected to inflect positively for the company in 2Q27, as the company laps tariff pressures. We continue to see significant margin recovery opportunitiesin FY27 and into FY28, with its target of DD operating margins, which leads to EPS potential over $3," updated Drbul. Needham was more cautious on the setup for Nike ( NKE ). "While some of the key aspects of the Win Now strategy make sense (refocus on sport, wholesale, marketing, etc.), the external environment is highly challenging, and the prior CEO may have dug the company into a bigger hole than it seemed," warned analyst Tom Nikic. Needham has a Hold rating on Nike ( NKE ). Bank of America downgraded Nike ( NKE ) to a Neutral rating after having it set at Buy. "Strong results in running and North America were the reasons for our patience, but with the sales inflection now nine months away, we see little room fo...
Valmont (VMI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Valmont (VMI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BigBear.ai (NYSE: BBAI) looks like a failed AI stock, but that may provide for a perfect entry point. A stronger balance sheet, a massive backlog, and a possible new catalyst could just be enough to send the stock soaring once again. Stock prices used were the market prices of March 23, 2026. The video was published on March 27, 2026. Continue reading
BigBear.ai (NYSE: BBAI) looks like a failed AI stock, but that may provide for a perfect entry point. A stronger balance sheet, a massive backlog, and a possible new catalyst could just be enough to send the stock soaring once again. Stock prices used were the market prices of March 23, 2026. The video was published on March 27, 2026. Continue reading
Trump is set to address the nation after saying the U.S. will withdraw from Iran in 2-3 weeks. And, the president will be at the Supreme Court today as arguments on birthright citizenship begin. (Image credit: Brendan Smialowski)
Trump is set to address the nation after saying the U.S. will withdraw from Iran in 2-3 weeks. And, the president will be at the Supreme Court today as arguments on birthright citizenship begin. (Image credit: Brendan Smialowski)